What is the total issue size of the Pramodini Medicare IPO?

The total issue size is ₹69.04 crore, comprising a fresh issue of ₹63.14 crore (5,014,800 shares) and an offer for sale of ₹5.90 crore (500,400 shares).

What is the price band and minimum lot size for Pramodini Medicare IPO?

The price band is ₹110 to ₹118 per share with a lot size of 1,200 shares. Minimum retail application requires 2 lots (2,400 shares) amounting to ₹2,64,000 at the lower band or ₹2,83,200 at the upper band.

On which exchange will Pramodini Medicare Ltd list?

Pramodini Medicare Ltd shares are proposed to list on the NSE EMERGE SME platform.

How will Pramodini Medicare Ltd utilize the fresh issue proceeds?

Net proceeds from the fresh issue will be used primarily to fund capital expenditure of ₹45.15 crore for purchasing medical equipment for existing and proposed diagnostic centres, with the remaining balance allocated to general corporate purposes.

Who are the lead managers and registrar for the Pramodini Medicare IPO?

The book-running lead manager is Smart Horizon Capital Advisors Private Limited and the registrar is Purva Sharegistry India Private Limited.

What are the core diagnostic services provided by Pramodini Medicare Ltd?

Pramodini Medicare provides radiology services (MRI, CT, X-ray, Ultrasound), clinical laboratory services (pathology, microbiology, biochemistry), nuclear medicine (PET-CT, SPECT), and 24x7 teleradiology services.

What is the revenue concentration profile of Pramodini Medicare Ltd?

For the nine months ended December 31, 2025, B2G (government-related) business contributed 61.32% of operational revenue, B2B contributed 20.09%, and B2C contributed 18.60%.

Home›India›Pramodini Medicare ()

Pramodini MedicareNSE SME / BSE SME:

Analyzed by ViewIPO Financial Research Team

Healthcare ServicesIndia•Filed 2026-08-12•Listing 2026-08-19•Size ₹68.89Cr

The total amount of money the company is trying to raise from the public through this IPO.

•Lot Size 1200

The minimum number of shares an investor must bid for in an IPO.

Live GMP

Grey Market Premium. The extra amount buyers are willing to pay for the IPO shares in the unofficial market before listing.

₹0 (0%)

Subscription

How many times the IPO has been demanded by investors. E.g., 10x means investors want 10 times more shares than available.

0.67x Total

Is Pramodini Medicare IPO Good? Quick Verdict

Pramodini Medicare IPO scored 75/100 (Moderate Risk) in our deep analysis. The strongest pillar is Promoter/Management at 90/100, while Competition is the primary concern at 45/100. Pramodini Medicare Ltd shows consistent revenue growth, strong operating margins, and low leverage, though it faces notable customer concentration with over 61% of revenues derived from government contracts.

IPO Score

75/100

Moderate Risk

Quick Verdict

Consistent revenue and PAT growth from FY23 through FY25.

Strong return metrics with ROE of 32.70% and ROCE of 34.66% alongside a low D/E ratio of 0.34.

High customer concentration with government-related business contributing 61.32% of total revenue.

Overall issue remained under-subscribed at 0.67x overall bidding as of close.

Company Snapshot

Revenue (TTM)

Total money brought in by the company's operations before deducting any expenses.

₹38.24Cr↑ 8.54% YoY

Profitability

The company's total profit after all expenses, taxes, and costs have been deducted.

PositiveNet Income ₹11.54Cr

Gross Margin

—

Market Cap (Post-IPO)

The total value of all the company's shares combined. It shows the overall size of the company.

₹65.1CrAt upper band ₹118

IPO Size

The total amount of money the company is trying to raise from the public through this IPO.

₹68.89Cr

Industry

Healthcare Services

P/E Ratio

Price-to-Earnings. How much you pay for ₹1 of company profit. A high P/E might mean the stock is expensive.

14.97xValuation Multiple

Return on Equity

Return on Equity. Shows how efficiently the company generates profit using the shareholders' money.

32.7%Profitability

Debt to Equity

Shows how much debt the company has compared to its own funds. >1 means more debt than equity.

0.34xLeverage

RoNW

Return on Net Worth. Similar to RoE, it measures the profitability against the net worth of the company.

32.7%Return on Net Worth

Risk Breakdown

Governance

Moderate

Financial

Excellent

Valuation

Excellent

Competition

Expensive

Dilution

Excellent

Promoter / Mgmt

Excellent

AI Summary

Pramodini Medicare Ltd is an Indian technology-enabled diagnostic service provider operating 15 diagnostic centres across six states offering radiology, clinical laboratory, and nuclear medicine services. For FY25, Pramodini Medicare Ltd achieved revenue from operations of ₹38.24 crore and a net profit of ₹11.54 crore, reflecting steady multi-year financial growth. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.34 and strong return metrics including an ROE of 32.70% and ROCE of 34.66%. Net proceeds from the fresh issue will primarily fund capital expenditure of ₹45.15 crore to acquire advanced medical diagnostic equipment.

Overall Verdict: Pramodini Medicare Ltd shows consistent revenue growth, strong operating margins, and low leverage, though it faces notable customer concentration with over 61% of revenues derived from government contracts.

Key Highlights

•Operates 15 diagnostic centres across six states and 13 cities in India as of December 31, 2025.
•Comprehensive service portfolio covering radiology (MRI, CT, Ultrasound), clinical laboratory, and nuclear medicine (PET-CT, SPECT).
•Flexible operating model combining PPPs, private hospital partnerships, PSU strategic alliances, and standalone units.
•Operates a 24x7 centralized teleradiology service registered office in Vijayawada.
•B2G (Business-to-Government) sector generates 61.32% of total operational revenues.
•Net fresh issue proceeds of ₹45.15 crore allocated toward purchasing new medical equipment for expansion.

Financial Performance

Revenue (Annual)
Total money brought in by the company's operations before deducting any expenses.

↑ +8.5% YoY

INR in Crores

Net Income (Annual)
The company's total profit after all expenses, taxes, and costs have been deducted.

↑ +51.4% YoY

INR in Crores

EBITDA vs PAT
Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.

↑ +35.0% YoY

INR in Crores

EBITDA

PAT

IPO Timeline

IPO Opens2026-08-12

IPO Closes2026-08-14

Basis of Allotment2026-08-17

Refunds & Demat2026-08-16

Listing Date2026-08-19

Valuation Analysis

IPO Price₹110 - ₹118

Estimated Fair Value

The theoretical true worth of the company based on its financial performance and peers.

Pending Data

Valuation Premium

How much more expensive this IPO is compared to its estimated fair value or its industry peers.

Pending

vs Fair Value

IPO DNA

Growth

Evaluates the company's historical and projected revenue and profit expansion.

Governance

Assesses the quality, transparency, and track record of the company's management team.

Profitability

Measures how effectively the company turns its sales into actual profit.

Valuation

Analyzes whether the IPO price is cheap, fair, or expensive compared to peers.

Competition

Evaluates the company's market share, moats, and competitive threats in its industry.

Execution

Assesses the company's ability to successfully utilize IPO proceeds and deliver on its promises.

Pros vs Cons

Pros

Consistent operational growth with revenue growing from ₹30.58 Cr in FY23 to ₹38.24 Cr in FY25.
High profitability metrics featuring an ROE of 32.70% and ROCE of 34.66%.
Conservative leverage position represented by a low debt-to-equity ratio of 0.34.
Diversified asset base comprising 7 CT, 7 MRI, 20 X-ray, and 15 Ultrasound machines across 15 diagnostic centres.

Cons

Heavy client concentration with government contracts contributing 61.32% of operational revenues.
High capital intensity requiring significant recurring capital outlay for modern medical equipment.
Under-subscribed public offer generating only 0.67x overall subscription response.

Financial Health

Revenue Growth

The year-over-year percentage increase in the company's total sales.

11.8% CAGR (FY23-FY25) (Good)

Debt Level

An assessment of whether the company's borrowing is manageable or risky.

0.34 Debt-to-Equity (Excellent)

Cash & Equivalents

How much liquid cash the company has on hand to fund daily operations.

Undisclosed (Moderate)

Institutional Signals

Anchor Investors

Large institutional investors who buy shares before the IPO opens to the public, signaling confidence.

Yes

VC Backing Tier

Whether renowned Venture Capital or Private Equity firms have invested in the company.

Undisclosed

Founder Ownership

The percentage of the company still owned by its original founders after the IPO.

98.75%

Strategic Partners

Key business alliances that give the company a competitive edge.

Government PSUs & Hospital PPP Partnerships

Pramodini Medicare IPO — Frequently Asked Questions

Related IPO Reports

Q&T Foods

QTFOODS

74/100

View Report

Shiprocket

SHIP

56/100

View Report

Behari Lal Engineering

BLEL

63/100

View Report

Fascinate Textiles

FASCINATE

76/100

View Report

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another IPO?

Search any IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Pramodini Medicare

Is Pramodini Medicare IPO good for long term?

Based on our AI analysis, Pramodini Medicare has a financial score of N/A/100 and a market potential score of N/A/100. Always consult a financial advisor before making long-term investments.

What is the lot size of Pramodini Medicare IPO?

You can use our Lot Size Calculator to instantly find the exact lot size and maximum investment limits for Retail, sHNI, and bHNI categories for Pramodini Medicare.

What is the expected listing price of Pramodini Medicare?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Pramodini Medicare on our Live GMP Tracker.

Pramodini MedicareNSE SME / BSE SME:

Is Pramodini Medicare IPO Good? Quick Verdict

Quick Verdict

Company Snapshot

Risk Breakdown

AI Summary

Key Highlights

Financial Performance

Revenue (Annual) Total money brought in by the company's operations before deducting any expenses.

Net Income (Annual) The company's total profit after all expenses, taxes, and costs have been deducted.

EBITDA vs PAT Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.

IPO Timeline

Valuation Analysis

IPO DNA

Pros vs Cons

Pros

Cons

Financial Health

Institutional Signals

Pramodini Medicare IPO — Frequently Asked Questions

Related IPO Reports

Q&T Foods

Shiprocket

Behari Lal Engineering

Fascinate Textiles

Want to analyze another IPO?

Frequently Asked Questions about Pramodini Medicare

Is Pramodini Medicare IPO good for long term?

What is the lot size of Pramodini Medicare IPO?

What is the expected listing price of Pramodini Medicare?

Revenue (Annual)
Total money brought in by the company's operations before deducting any expenses.

Net Income (Annual)
The company's total profit after all expenses, taxes, and costs have been deducted.

EBITDA vs PAT
Earnings Before Interest, Taxes, Depreciation, and Amortization. Shows pure operating performance.